Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
Cybin Inc (CYBN)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: CYBN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -55.59% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 178.38M USD | Price to earnings Ratio - | 1Y Target Price 101.42 |
Price to earnings Ratio - | 1Y Target Price 101.42 | ||
Volume (30-day avg) 229329 | Beta 0.89 | 52 Weeks Range 6.50 - 19.84 | Updated Date 01/14/2025 |
52 Weeks Range 6.50 - 19.84 | Updated Date 01/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.93 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.71% | Return on Equity (TTM) -49.07% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 71252948 | Price to Sales(TTM) 278.25 |
Enterprise Value 71252948 | Price to Sales(TTM) 278.25 | ||
Enterprise Value to Revenue 313.59 | Enterprise Value to EBITDA -3.79 | Shares Outstanding 19991900 | Shares Floating 14348913 |
Shares Outstanding 19991900 | Shares Floating 14348913 | ||
Percent Insiders 6.35 | Percent Institutions 36.61 |
AI Summary
Company Profile:
Cybin Inc. is a leading biotechnology company focused on developing and commercializing novel therapeutics for various mental health disorders. The company was founded in 2019 and is headquartered in Toronto, Canada. Cybin's core business areas include researching and developing psychedelic medicines to address mental health issues such as depression, anxiety, PTSD, and addiction.
The leadership team of Cybin Inc. consists of industry experts with experience in biotechnology, pharmaceuticals, and healthcare. The CEO and Co-Founder, Doug Drysdale, has a background in investment banking and has led multiple successful biotechnology companies. The corporate structure includes key executives responsible for research and development, clinical trials, regulatory affairs, and business development.
Top Products and Market Share:
Cybin Inc's top products include novel psychedelic compounds undergoing clinical trials for various mental health disorders. These products have shown promising results in early-stage studies and have generated significant interest from the medical community and investors. While Cybin is still in the early stages of product development, the company aims to capture a significant market share in the rapidly growing mental health therapeutics market.
Total Addressable Market:
The total addressable market for mental health therapeutics is substantial, with an estimated market size of billions of dollars globally. As more people seek alternative treatments for mental health disorders, the demand for innovative solutions like psychedelic medicines is expected to increase significantly.
Financial Performance:
Cybin Inc's financial performance is difficult to assess in the absence of public financial statements or disclosures. However, the company has raised significant capital through private funding rounds and is well-positioned to continue its research and development efforts.
Dividends and Shareholder Returns:
Cybin Inc does not currently pay dividends as it is a biotechnology company focused on research and development. Shareholder returns are based on the company's stock performance, which can be volatile due to the nature of the industry.
Growth Trajectory:
Cybin Inc has shown strong growth potential in recent years as interest in psychedelic medicines for mental health disorders continues to grow. The company's strategic initiatives, including partnerships with research institutions and clinical trials, are expected to drive future growth.
Market Dynamics:
Cybin Inc operates in the rapidly evolving field of biotechnology and mental health therapeutics. The industry is characterized by technological advancements, changing regulations, and a growing acceptance of alternative treatments for mental health disorders. Cybin is well-positioned to capitalize on these trends and adapt to market changes.
Competitors:
Key competitors of Cybin Inc include companies such as MindMed Inc. (MNMD) and Compass Pathways PLC (CMPS). Cybin competes with these companies in the development and commercialization of psychedelic medicines for mental health disorders. While competition is strong in the industry, Cybin has unique products and a strong research pipeline that position it well in the market.
Potential Challenges and Opportunities:
Key challenges for Cybin Inc include regulatory hurdles, clinical trial delays, and market competition. However, the company also has significant opportunities for growth, including expanding into new markets, developing innovative therapies, and forming strategic partnerships.
Recent Acquisitions (last 3 years):
Cybin Inc has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
An AI-based fundamental rating for Cybin Inc's stock is 7 out of 10. This rating is based on the company's solid financial health, strong market position in the growing mental health therapeutics industry, and promising future prospects.
Sources and Disclaimers:
Sources used for this analysis include company filings, industry reports, and financial news websites. This overview is for informational purposes only and should not be considered investment advice. Investors should conduct their own research before making any investment decisions.
About NVIDIA Corporation
Exchange NYSE MKT | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2019-09-13 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 50 | Website https://www.cybin.com |
Full time employees 50 | Website https://www.cybin.com | ||
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.